| scholarly article | Q13442814 |
| P50 | author | Mariana Spetea | Q38545108 |
| Helmut Schmidhammer | Q57234666 | ||
| P2093 | author name string | Aquilino Lantero | |
| Elena Guerrieri | |||
| Tanila Ben Haddou | |||
| Filippo Erli | |||
| Michael Mairegger | |||
| P2860 | cites work | Structure of the human κ-opioid receptor in complex with JDTic | Q24308048 |
| Kappa opioid antagonists: past successes and future prospects | Q24647830 | ||
| Kappa-opioid ligands in the study and treatment of mood disorders | Q24657982 | ||
| A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 | ||
| Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders | Q26781580 | ||
| κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction | Q26864309 | ||
| Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction | Q27860958 | ||
| Antagonists of the kappa opioid receptor | Q28237246 | ||
| Novel developments with selective, non-peptidic kappa-opioid receptor agonists | Q28259198 | ||
| Discovery and Pharmacological Evaluation of a Diphenethylamine Derivative (HS665), a Highly Potent and Selective κ Opioid Receptor Agonist | Q28278823 | ||
| Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? | Q30250027 | ||
| Neuropharmacology of the Naturally Occurring κ-Opioid Hallucinogen Salvinorin A | Q30467220 | ||
| 30 years of dynorphins--new insights on their functions in neuropsychiatric diseases | Q30481450 | ||
| Peptide kappa opioid receptor ligands: potential for drug development | Q33442900 | ||
| Opioids: first lessons from knockout mice | Q33547877 | ||
| Selective κ receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice. | Q33911524 | ||
| In vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel mu opioid analgesic with reduced propensity to alter motor function | Q34124185 | ||
| Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse. | Q34401390 | ||
| Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine | Q34461542 | ||
| Biased agonism at kappa opioid receptors: Implication in pain and mood disorders | Q34484496 | ||
| Opioids in Preclinical and Clinical Trials | Q34629711 | ||
| The kappa opioid receptor: from addiction to depression, and back. | Q34650892 | ||
| Anti-inflammatory effects of opioids | Q35078254 | ||
| Selective Natrexone-Derived Opioid Receptor Antagonists | Q35229118 | ||
| Synthesis of novel triplets with a 1,3,5-trioxazatriquinane skeleton and their pharmacologies for opioid receptors. | Q35627652 | ||
| Development of κ Opioid Receptor Antagonists | Q36728154 | ||
| Kinase cascades and ligand-directed signaling at the kappa opioid receptor | Q36900733 | ||
| kappa-Opioid receptor signaling and brain reward function | Q37455456 | ||
| Kappa opioids and the modulation of pain | Q37725698 | ||
| Does the kappa opioid receptor system contribute to pain aversion? | Q38276410 | ||
| Targeting Itch with Ligands Selective for κ Opioid Receptors | Q38415148 | ||
| Dynorphin A analogs for the treatment of chronic neuropathic pain | Q38715846 | ||
| Insights into the function of opioid receptors from molecular dynamics simulations of available crystal structures. | Q39165104 | ||
| Current κ opioid receptor ligands and discovery of a new molecular scaffold as a κ opioid receptor antagonist using pharmacophore-based virtual screening | Q39231361 | ||
| Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials | Q41639865 | ||
| [3H]U-69593 a highly selective ligand for the opioid kappa receptor | Q42204885 | ||
| Structural determinants of diphenethylamines for interaction with the κ opioid receptor: Synthesis, pharmacology and molecular modeling studies | Q44339731 | ||
| Kappa Opioid Receptor Activation in Dopamine Neurons Disrupts Behavioral Inhibition | Q44346829 | ||
| Synthesis and pharmacological evaluation of [(3)H]HS665, a novel, highly selective radioligand for the kappa opioid receptor. | Q44348699 | ||
| A simplified method of evaluating dose-effect experiments | Q80391249 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 7579-7590 | |
| P577 | publication date | 2017-08-30 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | Highly Potent and Selective New Diphenethylamines Interacting with the κ-Opioid Receptor: Synthesis, Pharmacology, and Structure-Activity Relationships | |
| P478 | volume | 60 |
| Q64105404 | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists |
| Q52317568 | Structurally-Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice |
| Q57095558 | and Pharmacological Activities of 14--Phenylpropyloxymorphone, a Potent Mixed Mu/Delta/Kappa-Opioid Receptor Agonist With Reduced Constipation in Mice |
Search more.